SUPPLEMENTARY FIGURES

Supplementary Figure 1: Prdm16 is expressed by neural stem/progenitor cells in the

ventricular zone of the lateral ventricle of newborn mice. a-d) Antibody staining for ß-

galactosidase indicated that *Prdm16* was expressed in the ventricular zone (VZ) around the

lateral ventricle of newborn mice in a pattern that overlaps staining for the stem/progenitor cell

marker Nestin (scale bar for **a** and **c** is 250μ m, scale bar for **b** and **d** is 25μ m).

8/9/10


Page 24

Supplementary Figure 2: *Prdm16* is expressed by neural crest stem cells in the newborn gut and required for their self-renewal. a) Neural crest stem cell (NCSC) neurospheres were cultured from the outer muscle/plexus layers of the guts of $Prdm16^{+/+}$ (left) and $Prdm16^{LacZ/LacZ}$ (right) mice, then stained for ß-galactosidase activity using X-gal (blue). No ß-galactosidase staining was detected in $Prdm16^{+/+}$ neurospheres but nearly all $Prdm16^{LacZ/LacZ}$ neurospheres stained strongly for ß-galactosidase activity. b) Gut NCSCs can be isolated by flow-cytometry as p75+CD49b+ cells (see P5 box). Unfractionated outer muscle/plexus layer gut cells or p75+CD49b+ gut cells were stained with FDG to assess ß-galactosidase activity. 2.5-3.6% background staining was observed in $Prdm16^{+/+}$ cells (left). A minority of unfractionated outer muscle/plexus layer gut cells and a majority of p75+CD49b+ gut cells from $Prdm16^{LacZ/LacZ}$ mice stained positively for ß-galactosidase (right; FDG+). c) A significantly lower percentage of cells from the gut outer muscle/plexus layer of $Prdm16^{LacZ/LacZ}$ mice formed multipotent neurospheres in culture as compared to cells from littermate controls. d) The diameter of $Prdm16^{LacZ/LacZ}$ and $Prdm16^{LacZ/LacZ}$ neurospheres was significantly decreased relative to $Prdm16^{+/+}$ neurospheres. The number of independent experiments is indicated in each panel, error bars always represent SD.

Supplementary Figure 3: HSCs were depleted in the spleens of newborn $Prdm16^{LacZ/LacZ}$ mice but differentiated cells were not. a-b) Newborn $Prdm16^{+/+}$, $Prdm16^{LacZ/+}$ and $Prdm16^{LacZ/LacZ}$ mice were born at the expected Mendelian frequency c) The spleens of newborn $Prdm16^{LacZ/LacZ}$ mice had normal frequencies of mature hematopoietic cells. No significant differences were detected in the frequencies of B (B220+), T (CD3+), erythroid (Ter119+), or myeloid (Mac-1+Gr-1+) lineage cells. Since spleen cellularity was also normal (Fig. 2a), the absolute numbers of differentiated cells was normal in the spleens of $Prdm16^{LacZ/LacZ}$ mice. Data are from at least 5 mice per genotype from at least 3 independent experiments. Error bars always represent SD. d) The spleens of newborn $Prdm16^{LacZ/+}$ and $Prdm16^{LacZ/LacZ}$ mice contained significantly fewer CD150⁺CD48⁻CD41⁻Sca1⁺c-kit⁺ HSCs compared to *Prdm16^{+/+}* mice. The number of mice per genotype is indicated in the legend of panel **c** and in bars in panel **d**. Error bars always represent SD. **e)** The gene expression profiles of VZ cells from newborn *Prdm16^{+/+}*, *Prdm16^{LacZ/+}*, and *Prdm16^{LacZ/LacZ}* mice were compared by microarray. The list shows all genes that were significantly (p<0.05) increased in expression within *Prdm16^{LacZ/LacZ}* VZ cells as compared to *Prdm16^{+/+}* or *Prdm16^{LacZ/+}* cells (by at least 2.2 fold between *Prdm16^{+/+}* and *Prdm16^{LacZ/LacZ}* VZ and at least 1.8 fold between *Prdm16^{LacZ/+}* and *Prdm16^{LacZ/LacZ}*). Genes that decreased in expression are shown in Figure 4a. Asterisks indicate genes associated with ROS regulation or response to oxidative stress. Differential expression was confirmed by qPCR in 3 independent samples/genotype.

Supplementary Figure 4: ROS, mitochondrial mass, and mitochondrial membrane potential in newborn (P0) stem/progenitor cells from the hematopoietic and nervous systems of *Prdm16^{+/+}*, *Prdm16^{LacZ/+}* and *Prdm16^{LacZ/LacZ}* mice. a-b) *Prdm16* deficiency significantly reduced DCFDA staining in newborn c-kit+Sca-1+ cells as assessed by mean (a) or median (b) fluorescence (the total number of mice per treatment is indicated under each bar; each panel reflects at least 3 independent experiments). Newborn (P0) *Prdm16^{LacZ/LacZ}* lateral ventricle VZ cells (c-d) and unfractionated liver or Sca1⁺c-kit⁺ hematopoietic cells (e-f) were assessed for mitochondrial mass using Mitotracker (c,e) and mitochondrial membrane potential using TMRM (d,f). No changes in mitochondrial mass or membrane potential were detected in neonatal VZ cells (data are from 2 *Prdm16^{+/+}*, 5 *Prdm16^{LacZ/+}* and 5 *Prdm16^{LacZ/LacZ}* mice). c) No significant reduction in mitochondrial membrane potential was observed in *Prdm16^{LacZ/LacZ}* and *Prdm16^{LacZ/LacZ}* hematopoietic cells from newborn liver. This trend toward reduced mitochondrial membrane potential could contribute to the reduced ROS levels in *Prdm16* deficient hematopoietic stem/progenitor cells. (*, P<0.05; **, P<0.01; ***, P<0.001, error bars always represent SD).

Supplemental Figure 1



Supplemental Figure 2

